ROME – Anti–tumor necrosis factor agents have a slight edge over conventional disease-modifying antirheumatic drugs when it comes to helping psoriatic arthritis patients who are having work issues,...

Field of Interest: Rheumatology

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.